Unlearn.AI

Revolutionizing clinical trials with AI-driven digital twins technology.

What is Unlearn. AI? Unlearn. AI is at the forefront of a transformative approach in the medical field, leveraging artificial intelligence to revolutionize clinical trials and drug development. The core innovation of Unlearn. AI is its development of digital twins—virtual models of patients—that enable more efficient and accurate predictions of clinical outcomes. This technology is designed to enhance the decision-making process in clinical trials, significantly reducing both time and cost while increasing the reliability of trial results. Key Features: Digital Twins Technology: Utilizes AI to create accurate and comprehensive forecasts of patient health outcomes, revolutionizing the setup and execution of clinical trials. TwinRCTs: A novel approach to randomized controlled trials that require fewer patients by using digital twins, thus accelerating the enrollment and efficiency of these studies. Regulatory Compliance: Adheres to stringent guidelines from bodies like the US Food and Drug Administration and the European Medicines Agency, ensuring that the trials are not only practical but also meet high regulatory standards. Extensive Disease Coverage: Capable of creating digital twins for a wide array of diseases including Alzheimer’s, Asthma, Diabetes, and many more, making it a versatile tool in various medical research contexts.